1622MO Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study

Subjects

Subjects :

Oncology
medicine.medical_specialty
Stromal cell
GiST
business.industry
Internal medicine
medicine
In patient
Hematology
Line (text file)
business

Details

ISSN :

09237534

Volume :

31

Database :

OpenAIRE

Journal :

Annals of Oncology

Accession number :

edsair.doi...........8a52343899de7730595e443c0e904042

Full Text :

https://doi.org/10.1016/j.annonc.2020.08.1848